Document Detail


The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.
MedLine Citation:
PMID:  12823159     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: It has been presumed that nocturnal acid breakthrough may pose a risk for the development of nocturnal gastro-oesophageal reflux. AIM: To investigate the occurrence of gastro-oesophageal reflux and acid breakthrough during polygraphically monitored sleep under conditions of powerful acid suppression with omeprazole 20 mg b.d. and an additional dose of ranitidine at bedtime. METHODS: Nineteen individuals with symptomatic gastro-oesophageal reflux disease were studied. Each individual was studied on two occasions subsequent to 1 week of 20 mg of omeprazole treatment b.d. Subjects underwent 24-h oesophageal and gastric pH recording, with polysomnographic monitoring. Participants received either 150 mg ranitidine at bedtime or placebo, prior to a provocative meal. RESULTS: Ranitidine administration resulted in a significant (P < 0.01) reduction in the percentage of time the intragastric pH < 4.0. There was no significant difference with regard to measures of gastro-oesophageal reflux, and reflux events were not noted to occur with a significantly greater frequency during periods of nocturnal acid breakthrough compared with control intervals without acid breakthrough. CONCLUSIONS: The administration of 150 mg ranitidine at bedtime did not significantly alter the occurrence of sleep-related gastro-oesophageal reflux.
Authors:
W C Orr; M J Harnish
Related Documents :
1422719 - Ambulatory measurement of oesophageal function: clinical use of a new ph and motility r...
7489929 - Alkaline gastro-oesophageal reflux: dual probe ph monitoring.
1263119 - Nicotine-like actions of cis-metanicotine and trans-metanicotine.
11748879 - Evaluation of exposure to airborne bacterial endotoxins and peptidoglycans in selected ...
14977569 - Molecular biology of pyridine nucleotide and nicotine biosynthesis.
15460839 - Combined multichannel intraluminal impedance and ph-metry: a novel technique to improve...
15678719 - Quality evaluation of honey harvested from selected areas in tanzania with special emph...
17993159 - Effects of increasing acidity on metal(loid) bioprecipitation in groundwater: column st...
19764799 - Chemical synthesis of a hyaluronic acid decasaccharide.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  17     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-25     Completed Date:  2003-09-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1553-8     Citation Subset:  IM    
Affiliation:
Lynn Institute for Healthcare Research, Oklahoma City, OK , USA. worr@lhsi.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Ulcer Agents / administration & dosage*
Circadian Rhythm
Drug Therapy, Combination
Esophagus / physiology
Female
Gastric Acid / secretion*
Gastroesophageal Reflux / drug therapy*,  physiopathology
Histamine H2 Antagonists / administration & dosage*
Humans
Hydrogen-Ion Concentration
Male
Middle Aged
Omeprazole / administration & dosage*
Chemical
Reg. No./Substance:
0/Anti-Ulcer Agents; 0/Histamine H2 Antagonists; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylo...
Next Document:  13C-Methacetin metabolism in patients with cirrhosis: relation to disease severity, haemoglobin cont...